Surrozen, Inc./DE (SRZN) research
Surrozen, Inc./DE- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $29.32
- As of
Surrozen, Inc./DE (SRZN): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-02.
As of . Source: SEC EDGAR filings for SRZN. Method and limitations.
Share the SRZN intelligence card
See the full SRZN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SRZN on one page. Preview it with sample data, then open it live with a free account.
Preview the SRZN dossierActive signals for SRZN
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in SRZN
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 75% of SRZN (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +80% to SRZN (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 68.8%, EPS $-0.41 vs $-1.3138 estimate
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +117% to SRZN (2026Q1)
FREE, NO ACCOUNT
Every signal on SRZN, as it fires
You are seeing 5 of 11 signals recorded on SRZN since 2026-05-26.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SRZN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 86889P208 · 2026Q2 | $17.7M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 86889P208 · 2026Q2 | $17.2M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 86889P208 · 2026Q2 | $1.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 86889P208 · 2026Q2 | $321K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SRZN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SRZN against its peers
SRZN's operating margin of -1210.6% ranks in the 18th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | SRZN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.5M USD | 34.7M USD | 17 | 14 |
| Operating margin | -1210.6% | -271.9% | 18 | 13 |
| Net margin | -6960.8% | -292.1% | 11 | 13 |
| Return on equity | n/a | -67.9% | n/a | 20 |
Peers (24): PROK, OBIO, FENC, OCGN, BNTC, ARTV, ARCT, EBS, ENTA, BBOT, IRD, AGEN, CABA, LRMR, CCCC, RZLT, GALT, TTRX, ZURA, EVMN, PRLD, RLMD, EDIT, LXEO. Left out: VOGX (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (SRZN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SRZN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SRZNand get the insider, 13F, options, and confluence read in one view.